Citigroup Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $12.5
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Nicholas Joseph has maintained a Neutral rating on Sabra Health Care REIT (NASDAQ:SBRA) and raised the price target from $11 to $12.5.

July 14, 2023 | 3:32 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Citigroup has maintained a Neutral rating on Sabra Health Care REIT and raised the price target from $11 to $12.5.
The news is directly about Sabra Health Care REIT. Citigroup's decision to maintain a Neutral rating indicates that they do not expect significant price movement in the short term. However, the increase in price target from $11 to $12.5 suggests a positive outlook in the longer term. This could potentially attract investors, but the immediate impact on the stock price is likely to be neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100